

AGM Date & Director Nominations Closing Date for AGM

5 August 2024 – Melbourne, Australia: PharmAust Limited (ASX: PAA & PAAOA) (“PharmAust” or “the Company”), a clinical-stage biotechnology company, advises that its next Annual General Meeting (“AGM”) will be held on Monday, 30 September 2024. An election of directors will be held at this AGM pursuant to ASX Listing Rule 14.5. Details of the Directors to be elected will be included in the forthcoming Notice of AGM.

In accordance with ASX Listing Rule 3.13.1 and rule 7.2(f)(ii) of the Company’s Constitution, the Company advises that the Closing Date for receipt of nominations for the position of Director is Monday, 12 August 2024. Any nominations must be received in writing no later than 5.00pm (Melbourne time) on Monday, 12 August 2024 at the Company’s registered office.

The Company notes that the deadline for nominations for the position of Director is separate to voting on Director elections. Details of the Directors to be elected will be provided in the Company Notice of AGM in due course.

This announcement is authorised for release by the Board of Directors of PharmAust Limited.

For further information, please contact:

Dr Michael Thurn

Managing Director

investorenquiries@pharmaust.com

P +61 (3) 9692 7222

W www.pharmaust.com

Media:

Jacqueline Pfenninger

Sodali & Co

jacky.pfenninger@sodali.com

P 0447 301 111

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel (MPL) for amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neurone disease (MND) and affects both upper and lower motor neurons.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic proteins are broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including ALS.

The company recently announced positive top-line results for its Phase 1 MEND study in participants with ALS. MPL has been selected for inclusion in the HEALEY ALS Platform Trial and anticipates commencing



enrolment in Q4 CY 2024. This single pivotal study could potentially lead to accelerated approval with the US FDA for MPL for the treatment of ALS in 2026.

In 2024, the Neurodegenerative Disease Market size is estimated to be worth USD 55.12 billion, with a forecast growth (CAGR) of 7.14% the market size is expected to reach USD 77.82 billion by 2029.¹

¹ <https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market>

PharmAust Investor Hub:

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Access the investor hub by scanning the QR code or visiting: <https://investorhub.pharmaust.com/>

